We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ProMIS Neurosciences Inc (PMN) NPV

Sell:$1.51 Buy:$1.62 Change: $0.0751 (4.28%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0751 (4.28%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0751 (4.28%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.

Contact details

Suite 200, 1920 Yonge Street
M4S 3E2
+1 (416) 8476898

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$33.28 million
Shares in issue:
18.96 million
US dollar

Key personnel

  • Eugene Williams
    Executive Chairman of the Board
  • Gail Farfel
    Chief Executive Officer, Director
  • Neil Cashman
    Co-Founder, Chief Scientific Officer, Director
  • Daniel Geffken
    Chief Financial Officer
  • Gavin Malenfant
    Chief Operating Officer
  • Larry Altstiel
    Chief Medical Officer
  • Johanne Kaplan
    Chief Development Officer
  • David Wishart
    Chief Physics Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.